Fusion With DNA-Binding Domain TRIZ Cases

Replacing custom protein design with a universal nuclease and programmable RNA eliminates costly target-specific engineering while reducing off-target effects.

Periodic variation in every four modules reduces non-specific binding while maintaining high cleavage activity and simplifying vector preparation.

Engineered zinc finger nucleases create double-strand breaks to increase homologous recombination frequency, overcoming rare meganuclease site limitations.

Segmented genetic operons combine light-sensitive and catalytic domains to achieve spatiotemporal control over protein phosphatase activity.

A methylcytosine-selective deaminase converts 5mC and 5hmC to thymidine while leaving cytosine unaltered.

Prophylactic anti-IL-6 agents block interleukin 6 signaling to prevent chronic post-operative pain persistence.

Combinatorial artificial transcription repressors fuse DNA-binding domains with epigenetic effectors to establish heritable gene silencing.

A chimeric protein fuses a single-stranded nucleic-acid-binding domain with a catalytic polymerase to increase replication speed.

Adding arginine and Sso7 conjugates to PCR mixtures suppresses non-specific product formation while increasing tolerance to inhibitors.

Targeted mutations at positions 28, 43, and 53 in the Sso7 domain of polymerase conjugates reduce non-specific amplification while maintaining processivity.

Chimeric polypeptides fuse TALE DNA-binding domains with nuclease modules to enable precise site-specific genome recombination.

Exonuclease-deficient hybrid polymerases resolve specificity-efficiency trade-offs in complex samples like blood.

Htt-modulating transcription factors repress mutant Huntingtin alleles, reducing protein aggregation and apoptosis while improving neuronal energy metabolism.

Designer epigenome modifier construct induces targeted methylation to silence specific genes in immune cells.

Segmented fusion proteins with non-covalent linkages enhance nuclease activity at target loci, resolving efficiency losses from covalent constraints.

DddA deaminase marks cytosine residues via protein fusion, enabling single-cell resolution mapping of DNA-protein interactions in living cells.

Inducible promoters drive transient marker expression during selection, resolving the trade-off between editing efficiency and long-term cell viability.

Targeting FOXP3 control regions sustains suppression phenotypes, resolving limited therapeutic effectiveness in autoimmune treatment.

Nucleases disrupt BCL11A enhancers to increase gamma globin production, resolving variable efficacy and side effects of current hemoglobinopathy treatments.

Zinc finger fusion proteins repress prion gene expression, overcoming limited distribution of antisense oligonucleotides.

Cas9 fusion proteins reduce off-target cleavage by attenuating nuclease affinity and relying on specific DNA targeting units.

Targeted genome editing with CRISPR-Cas9 and sgRNA corrects ATXN2 trinucleotide repeats, reducing aberrant protein expression and restoring wild-type function.

A Cas9-DBD fusion protein links nuclease cleavage with specific DNA binding to facilitate targeted insertion.

Segmented prime editing guide RNAs correct SLC37A4 mutations to restore glucose homeostasis in glycogen storage disease type 1B.

Monomeric I-TevI chimeric endonucleases eliminate FokI dimerization needs, reducing off-site cleavage while maintaining high efficiency.

Charge mutations in FokI domains reduce off-target cleavage while maintaining high on-target activity.

Partially single-stranded donor molecules integrate exogenous sequences into plant genomes via non-homologous end joining pathways.

A polymeric modification agent binds DNA to stall replication forks without causing breaks.

Site-specific agents modulate hepatocyte nuclear factor 4-alpha expression using polymeric vectors and lipid formulations for targeted delivery.

Targeted nuclease integration eliminates repeated infusions and antibody risks.

An artificial protein with dual histone binding domains isolates modified nucleosomes in a single step.

Varying amino acid position 6 in zinc fingers resolves the contradiction between broad target versatility and consistent binding specificity.

Adding polyA tails to short non-polyA RNAs enables efficient amplification and detection of molecules like miRNA that lack natural tails.

Engineered cleavage half-domains form obligate heterodimers to enhance targeted genomic editing activity.

Engineered proteins enable real-time lactose detection without complex HPLC apparatus, improving measurement sensitivity.

Modular DNA binding domains direct catalytic cleavage to specific local contexts, reducing off-site mutagenesis while contracting mutant alleles.

Modifying globin gene expression via genome editing alleviates hemoglobinopathy symptoms by correcting aberrant genes.

Exc+Int- piggyBac transposase with dCas9 mediates targeted gene insertion, eliminating insertional mutagenesis risk while maintaining excision activity.

Dual prime editing systems utilize specific PEgRNAs to excise toxic hexanucleotide repeats from the C9ORF72 gene, addressing motor neuron toxicity in ALS.

CRISPR/Cas9 editing targets the APOE e4 allele to address Alzheimer's disease heterogeneity.

Fusing GIF domains with DNA binding modules boosts transcription factor activity, overcoming limited broad modification capabilities of conventional methods.

A MoonTag system uses nanobody-peptide interactions to recruit activation domains for gene expression.

Engineered zinc finger proteins facilitate targeted double-strand cleavage at the PPP1R12C locus for precise genomic editing.

Kinase and phosphatase pairs tune activation strength in genetic circuits, resolving the trade-off between design simplicity and precise microRNA detection.

VtrA polypeptide fusion protein activates reporter expression upon bile salt binding, enabling scalable early diagnosis of liver dysfunction.

Canine and feline sequences in the inducible gene expression system minimize immunogenicity while enabling periodic oral medication administration.

Site-specific nuclease integration anchors transgenes at safe harbor loci, preventing random insertion risks while ensuring durable expression.

Engineered homing endonucleases cleave the human TCRα gene to enable precise genome editing, resolving autoimmune response risks in cancer immunotherapy.

A hyperactive piggyBac transposase with specific amino acid substitutions enhances transposon integration efficiency in CHO cell lines.

Modified CCHC zinc fingers enhance DNA cleavage efficiency while maintaining structural stability via parameter changes.